In France, the Fédération Française des Diabetiques said it “welcomes the inclusion of Omnipod 5” on its list of reimbursable products and services.
Omnipod 5, an insulin patch pump, delivers automated management for type 1 diabetes. France’s Haute Autorité de Santé — the country’s high health authority — issued an indication for the system to target adults and children over two years of age, living with type 1 diabetes whose glycemic control is insufficient despite intensive treatment for more than six months.
Advocacy Action: Can you use the news from France to add pressure in your country for more reimbursements of diabetes tech and medicines where they are lacking? It is always good to have an example of where one country does something to put pressure on your own to bring improvements.